BRISBANE, Calif. & ST. LOUIS--(BUSINESS WIRE)--Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback